Drug Trial Radar · NCT04152083
A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine
Last checked: Nov 20, 2026Latest source record: Aug 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
485
Actual
Start
Nov 7, 2019
Primary completion
Jul 8, 2020
Study completion Jul 8, 2020
Sponsor
- Lead sponsor
- H. Lundbeck A/SIndustry
- Sponsor type
- Industry
- Collaborators
- Alder Biopharmaceuticals, Inc.
- First posted
- Nov 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of eptinezumab administered intravenously in participants experiencing an acute attack of migraine.
Conditions
- Migraine
Interventions
EptinezumabDrug
Injection for IV administration
PlaceboDrug
Injection for IV administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Headache Pain FreedomTime frame: Up to 48 hours postdose
- Time to Absence of Most Bothersome Symptom (MBS)Time frame: Up to 48 hours postdose
Locations
57 sites in 2 countries. Site status is shown where the registry gives one.
Alabama Clinical Therapeutics
Birmingham, Alabama
Arizona Research Center
Phoenix, Arizona
Baptist Health Center for Clinical Research
Little Rock, Arkansas
Advanced Research Center
Anaheim, California
The Neurology Center of Southern California - Carlsbad
Carlsbad, California
Excell research Inc
Oceanside, California
Anderson Clinical Research
Redlands, California
University of Colorado Hospital
Aurora, Colorado
Denver Neurological Clinic - Denver
Denver, Colorado
Coastal Connecticut Research LLC
New London, Connecticut
Ki Health Partners LLC, dba New England Institute for Clinical Research
Stamford, Connecticut
The George Washington Medical Faculty Associates
Washington D.C., District of Columbia
Medicinae Doctor Clinical
Hallandale, Florida
AGA Clinical trials
Hialeah, Florida
Meridien Research - Maitland
Maitland, Florida
Palm Beach Neurology and Premiere Research Institute
West Palm Beach, Florida
Clinical Research of Central Florida
Winter Haven, Florida
Office of Doctor Frank Berenson
Atlanta, Georgia
iResearch Atlanta, LLC
Decatur, Georgia
Meridian Clinical Research - Savannah Neurology Specialists
Savannah, Georgia
Cedar Crosse Research Center
Chicago, Illinois
College Park Family Care Center Physicians
Overland Park, Kansas
Phoenix Medical Research
Prairie Village, Kansas
Central Kentucky Research Associates
Lexington, Kentucky
Boston Clinical Trials
Boston, Massachusetts
MedVadis Research Corporation, LLC
Waltham, Massachusetts
Michigan Head Pain and Neurological institute
Ann Arbor, Michigan
Clinical Research Institute - Minneapolis
Minneapolis, Minnesota
Headache Neurology Research Institute
Ridgeland, Mississippi
StudyMetrix Research
City of Saint Peters, Missouri
Clinvest Research
Springfield, Missouri
Nevada Headache Institute
Las Vegas, Nevada
Albuqerque Clinical Trials
Albuquerque, New Mexico
Dent Neurologic Institute - Amherst
Amherst, New York
Integrative Clinical Trials
Brooklyn, New York
CTI Clinical Research center
Cincinnati, Ohio
Aventiv Research - Columbus
Columbus, Ohio
Hometown Urgent Care And Research - Huber Heights
Dayton, Ohio
Neuro-Behavioral Clinical Research Inc
North Canton, Ohio
Delricht Research
Tulsa, Oklahoma
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.